We scan new podcasts and send you the top 5 insights daily.
Fizazi explains that under hormonal pressure, androgen receptor mutations can let progesterone, prednisone, or estrogens stimulate prostate cancer. Opevesostat blocks CYP11, the first enzyme downstream of cholesterol, suppressing all steroid hormones; patients need glucocorticoid and mineralocorticoid replacement, and OMAR trials are testing it before and after docetaxel.
Unlike bladder cancer, prostate cancer has highly effective androgen-pathway inhibitors (ARPIs) that extend survival. This success has pushed chemotherapy and, by extension, ADC development to later treatment lines as clinicians prioritize other novel mechanisms of action first.
Shifting the view of prostate cancer from "androgen-driven" to "androgen receptor-driven" provides a new framework. In curative settings, after the androgen receptor is targeted for a defined period, restoring testosterone is seen as logical to improve patient quality of life once the cancer is destroyed.
The EMBARK trial showed that enzalutamide monotherapy was superior to standard ADT monotherapy for metastasis-free survival. This suggests potent AR antagonism may be a more effective strategy than simply depleting the testosterone ligand, challenging the long-held dogma of ADT being the fundamental building block for systemic prostate cancer therapy.
The investigational drug OP, a CYP11A1 inhibitor, works far upstream of abiraterone to block the creation of all adrenal steroids. This is effective against cancers with mutated androgen receptors (AR) that have become "promiscuous" and can be activated by non-androgen steroids like glucocorticoids.
Inhibiting the androgen receptor (AR) pathway triggers compensatory upregulation of the PI3K-AKT survival pathway in prostate cancer cells, regardless of PTEN status. Under normal conditions, AR suppresses AKT. When AR pathway inhibitors block this restraint, combined with PTEN loss removing the brakes on PIP3, AKT signaling is heavily amplified, driving unchecked tumor growth and circumventing hormone therapy.
The term "hormone resistance" was misleading. Researchers discovered that even in a castrate state, prostate cancer tumors produce their own testosterone locally. This maintained androgen receptor signaling, proving the disease was still "androgen addicted" and opening the door for new targeted therapies.
In castration-resistant states, prostate cancer cells often amplify their androgen receptors (AR) to survive low testosterone levels. Bipolar androgen therapy exploits this by introducing a massive surge of testosterone. This "shocks" the over-amplified AR system, causing it to regress and disrupting downstream tumor growth pathways.
Counterintuitively, administering super-physiologic levels of testosterone can induce responses in certain castration-resistant prostate cancers. This strategy, called Bipolar Androgen Therapy, exploits the tumor's overexpressed receptors, turning a growth signal into a therapeutic vulnerability, though it remains a risky approach.
The term "castration sensitive or resistant" is being phased out for more patient-centric language. "Androgen pathway modulation" better reflects the biological state, especially as new treatments are used without traditional testosterone-lowering therapy, a shift recommended by the Prostate Cancer Working Group 4.
The Tolmimidostat/Luxta-degalutamide combination attacks prostate cancer on two fronts. Luxta-degalutamide is an AR degrader, while Tolmimidostat, an EZH1/2 inhibitor, has anti-AR properties and also regulates lineage plasticity, potentially preventing the cancer's shift to a more aggressive neuroendocrine state.